Anticoagulation plus aspirin following acute myocardial infarction: Yes or no ... and if the latter, why not?

Thrombosis Research

Volumn 118, Issue 4, 2006, Pages 429-432

  Lip, Gregory Y H ^a   Varma, Chetan ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; OMEGA 3 FATTY ACID; PYRIDINE DERIVATIVE; TICLOPIDINE; WARFARIN; XIMELAGATRAN;

ANEMIA; ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; EDITORIAL; HEART INFARCTION; HEMATURIA; HUMAN; IRON DEFICIENCY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOGENESIS; TREATMENT OUTCOME;

ANTICOAGULANTS; ASPIRIN; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; WARFARIN;

EID: 33747882447     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.09.012     Document Type: Editorial

References (22)

1. McGovern P.G., Jacobs D.R., Shahar E., Arnett D.K., Folsom A.R., Blackburn H., et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 104 1 (2001) 19-24
2. Jaumdally R., Lip G.Y.H., and Varma C. Percutaneous coronary interventions for coronary artery disease: the long and short of optimising medical therapy. Int J Clin Pract 59 (2005) 1070-1081
3. Antithrombotic Trialists Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324 (2002) 71-86
4. Hurlen M., Abdelnorr M., Smith P., Erikssen J., and Arnesen H. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 347 (2002) 969-974
5. Hurlen M., Eikvar L., Seljeflot I., and Arnesen H. Occult bleeding in three different antithrombotic regimes after myocardial infarction A WARIS-II subgroup analysis. Thromb Res 118 (2006) 433-438 10.1016/j.thromres.2005.07.023 (this issue)
6. Avidor Y., Nadu A., and Matzkin H. Clinical significance of gross haematuria and its evaluation in patients receiving anticoagulant and aspirin treatment. Urology 55 (2000) 22-24
7. Grossfeld G.D., and Carroll P.R. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am 25 (1998) 661-676
8. Greenberg P.D., Cello J.P., and Rockey D.C. Relationship of low dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc 50 (1999) 618-622
9. Bini E.J., Rajapaksa R.C., and Weinshel E.H. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol 100 7 (2005) 1586-1592
10. Lee K.W., and Lip G.Y.H. Acute coronary syndromes: Virchow's triad revisited. Blood Coagul Fibrinolysis 14 7 (2003) 605-625
11. Wysokinski W.E., Owen W.G., Fass D.N., Patrzalek D.D., Murphy L., and McBane II R.D. Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. J Thromb Haemost 2 9 (2004) 1637-1644
12. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res in press. doi:10.1016/j.thromres.2005.08.007.
13. Lincoff A.M., Kleiman N.S., Kereiakes D.J., Feit F., Bittl J.A., Jackman J.D., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292 6 (2004) 696-703
14. Husted S.E., Wallentin L., Lagerqvist B., Kontny F., Stahle E., and Swahn E. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J 23 15 (2002) 1213-1218
15. Arnesen H. Oral anticoagulation after myocardial infarction. Thromb Res 109 4 (2003 (Feb 15)) 163-170
16. Wallentin L., Wilcox R.G., Weaver W.D., Emanuelsson H., Goodvin A., Nystrom P., et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 6362 9386 (2003 (Sep)) 789-797
17. Fiore L.D., Ezekowitz M.D., Brophy M.T., Lu D., Sacco J., and Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 105 5 (2002) 557-563
18. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 350 9075 (1997 (Aug 9)) 389-396
19. Rothberg M.B., Celestin C., Fiore L.D., Lawler E., and Cook J.R. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 143 4 (2005 (Aug 16)) 241-250
20. DiMarco J.P., Flaker G., Waldo A.L., Corley S.D., Greene H.L., Safford R.E., et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 149 4 (2005) 650-656
21. Buresly K., Eisenberg M.J., Zhang X., and Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165 7 (2005 (Apr 11)) 784-789
22. Cleland J.G. Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 44 4 (2002) 275-292